{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-094862","form_type":"8-K","ticker":"DERM","cik":"0001867066","company_name":"Journey Medical Corp","filed_at":"2026-08-12T20:05:37+00:00","discovered_at":"2026-08-12T20:07:16.762635+00:00","generated_at":"2026-08-12T20:07:39.981647+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Journey Medical Q2 revenue up 23% to $18.5M; net loss narrows to $0.3M","bullets":["Total revenues $18.5M for Q2 2026, +23% from $15.0M in Q2 2025; Emrosi sales $8.1M.","GAAP net loss narrowed to $0.3M ($0.01/sh) from $3.8M ($0.16/sh) year ago.","Non-GAAP EBITDA and Adjusted EBITDA positive for both three and six months ended June 30, 2026.","Cash $25.6M at June 30, 2026 vs $24.1M at Dec 31, 2025; SG&A down $1.0M to $10.9M.","Emrosi total prescriptions ~36,000 in Q2 2026, up from ~30,000 in Q1 and ~27,000 in Q4 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-094862","json":"https://secwatch.observer/filing/0001104659-26-094862.json","markdown":"https://secwatch.observer/filing/0001104659-26-094862.md","text":"https://secwatch.observer/filing/0001104659-26-094862.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1867066/000110465926094862/0001104659-26-094862-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1867066/000110465926094862/tm2622742d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-12T20:07:39.981647+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}